{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigeqw4jvxtwtpjouiqhut3cd56b3vv3aysoyhcfrivqyxvinko4oq",
    "uri": "at://did:plc:nzm6xlhdk3myu4xft63gxqp4/app.bsky.feed.post/3mjj3wld6bhn2"
  },
  "path": "/markets/double-downgrade-abbott-india-share-price-target-rating-slashed-on-weak-growth-outlook-11358910",
  "publishedAt": "2026-04-15T03:31:28.000Z",
  "site": "https://www.ndtvprofit.com",
  "tags": [
    "Markets"
  ],
  "textContent": "Competitive pressures, particularly from global players like Novo Nordisk, are intensifying, especially with the transition toward next-generation diabetes therapies, like GLP-1.",
  "title": "Double Downgrade: Abbott India Share Price Target, Rating Slashed On Weak Growth Outlook"
}